APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.

Selected research

Market Outlook & Growth Opportunities

Global Human Vaccine Market Outlook and Growth Opportunities 2026

21 December 2025216 pages

Choose your research edition.

Industry ResearchHuman Vaccine Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Human Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.

In China, Human Vaccine key players include CNBG, Kangtai, ChengDa Bio, etc. Global top three manufacturers hold a share about 65%.

East China is the largest market, with a share about 25%, followed by South China, and North China, both have a share about 40 percent.

Read the full market overview

In terms of product, Hepatitis B is the largest segment, with a share nearly 15%. And in terms of application, the largest application is Children, followed by Adults.

This report provides an overview of the global Human Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Vaccine Segment by Company

CNBG

Changsheng Life

Zhifei

ChengDa Bio

Kangtai

SINOVAC BIOTECH

Hissen

Walvax Biotechnology

GSK

SANOFI

Rong An

NuoCheng Bio

Hualan Bio

Tiantan biological

Changchun Baike

Adimmune

Zhongyianke Biotech

Bharat Biotech

Bavarian Nordic

Sanofi-Pasteur

Indian Immunologicals

KANGH

Henan Grand Biopharma

ZhongKe Biopharm

Zhuoyi Biological

Human Vaccine Segment by Type

Varicella

Influenza

Polio

Hepatitis A

Rabies

BCG

Hepatitis B

Pertussis, Diphtheria, Tetanus

Pneumococcal

Rota vaccine

Human Vaccine Segment by Application

Adults

Children

Human Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Human Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Vaccine industry.

Chapter 3: Detailed analysis of Human Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Vaccine Industry Trends Table 2. Human Vaccine Industry Drivers Table 3. Human Vaccine Industry Opportunities and Challenges Table 4. Human Vaccine Industry Restraints Table 5. Global Human Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Vaccine Revenue Share by Company (2021-2026) Table 7. Global Human Vaccine Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Human Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Human Vaccine Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Human Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Human Vaccine Company, Product Type & Application Table 13. Global Human Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Varicella Table 18. Significant Companies of Influenza Table 19. Significant Companies of Polio Table 20. Significant Companies of Hepatitis A Table 21. Significant Companies of Rabies Table 22. Significant Companies of BCG Table 23. Significant Companies of Hepatitis B Table 24. Significant Companies of Pertussis, Diphtheria, Tetanus Table 25. Significant Companies of Pneumococcal Table 26. Significant Companies of Rota vaccine Table 27. Global Human Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 28. Global Human Vaccine Sales Volume by Type (2021-2026) & (M Doses) Table 29. Global Human Vaccine Sales Volume by Type (2027-2032) & (M Doses) Table 30. Global Human Vaccine Sales Volume Share by Type (2021-2026) Table 31. Global Human Vaccine Sales Volume Share by Type (2027-2032) Table 32. Global Human Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Human Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 34. Global Human Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 35. Global Human Vaccine Sales Value Share by Type (2021-2026) Table 36. Global Human Vaccine Sales Value Share by Type (2027-2032) Table 37. Significant Companies of Adults Table 38. Significant Companies of Children Table 39. Global Human Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 40. Global Human Vaccine Sales Volume by Application (2021-2026) & (M Doses) Table 41. Global Human Vaccine Sales Volume by Application (2027-2032) & (M Doses) Table 42. Global Human Vaccine Sales Volume Share by Application (2021-2026) Table 43. Global Human Vaccine Sales Volume Share by Application (2027-2032) Table 44. Global Human Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Human Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Human Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Human Vaccine Sales Value Share by Application (2021-2026) Table 48. Global Human Vaccine Sales Value Share by Application (2027-2032) Table 49. Global Human Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 50. Global Human Vaccine Sales by Region (2021-2026) & (M Doses) Table 51. Global Human Vaccine Sales Market Share by Region (2021-2026) Table 52. Global Human Vaccine Sales by Region (2027-2032) & (M Doses) Table 53. Global Human Vaccine Sales Market Share by Region (2027-2032) Table 54. Global Human Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Human Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Human Vaccine Sales Value Share by Region (2021-2026) Table 57. Global Human Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Human Vaccine Sales Value Share by Region (2027-2032) Table 59. Global Human Vaccine Market Average Price (USD/Dose) by Region (2021-2026) Table 60. Global Human Vaccine Market Average Price (USD/Dose) by Region (2027-2032) Table 61. Global Human Vaccine Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 62. Global Human Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Human Vaccine Sales by Country (2021-2026) & (M Doses) Table 64. Global Human Vaccine Sales Market Share by Country (2021-2026) Table 65. Global Human Vaccine Sales by Country (2027-2032) & (M Doses) Table 66. Global Human Vaccine Sales Market Share by Country (2027-2032) Table 67. Global Human Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Human Vaccine Sales Value Market Share by Country (2021-2026) Table 69. Global Human Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Human Vaccine Sales Value Market Share by Country (2027-2032) Table 71. CNBG Company Information Table 72. CNBG Business Overview Table 73. CNBG Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 74. CNBG Human Vaccine Product Portfolio Table 75. CNBG Recent Development Table 76. Changsheng Life Company Information Table 77. Changsheng Life Business Overview Table 78. Changsheng Life Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 79. Changsheng Life Human Vaccine Product Portfolio Table 80. Changsheng Life Recent Development Table 81. Zhifei Company Information Table 82. Zhifei Business Overview Table 83. Zhifei Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 84. Zhifei Human Vaccine Product Portfolio Table 85. Zhifei Recent Development Table 86. ChengDa Bio Company Information Table 87. ChengDa Bio Business Overview Table 88. ChengDa Bio Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 89. ChengDa Bio Human Vaccine Product Portfolio Table 90. ChengDa Bio Recent Development Table 91. Kangtai Company Information Table 92. Kangtai Business Overview Table 93. Kangtai Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 94. Kangtai Human Vaccine Product Portfolio Table 95. Kangtai Recent Development Table 96. SINOVAC BIOTECH Company Information Table 97. SINOVAC BIOTECH Business Overview Table 98. SINOVAC BIOTECH Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 99. SINOVAC BIOTECH Human Vaccine Product Portfolio Table 100. SINOVAC BIOTECH Recent Development Table 101. Hissen Company Information Table 102. Hissen Business Overview Table 103. Hissen Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 104. Hissen Human Vaccine Product Portfolio Table 105. Hissen Recent Development Table 106. Walvax Biotechnology Company Information Table 107. Walvax Biotechnology Business Overview Table 108. Walvax Biotechnology Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 109. Walvax Biotechnology Human Vaccine Product Portfolio Table 110. Walvax Biotechnology Recent Development Table 111. GSK Company Information Table 112. GSK Business Overview Table 113. GSK Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 114. GSK Human Vaccine Product Portfolio Table 115. GSK Recent Development Table 116. SANOFI Company Information Table 117. SANOFI Business Overview Table 118. SANOFI Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 119. SANOFI Human Vaccine Product Portfolio Table 120. SANOFI Recent Development Table 121. Rong An Company Information Table 122. Rong An Business Overview Table 123. Rong An Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 124. Rong An Human Vaccine Product Portfolio Table 125. Rong An Recent Development Table 126. NuoCheng Bio Company Information Table 127. NuoCheng Bio Business Overview Table 128. NuoCheng Bio Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 129. NuoCheng Bio Human Vaccine Product Portfolio Table 130. NuoCheng Bio Recent Development Table 131. Hualan Bio Company Information Table 132. Hualan Bio Business Overview Table 133. Hualan Bio Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 134. Hualan Bio Human Vaccine Product Portfolio Table 135. Hualan Bio Recent Development Table 136. Tiantan biological Company Information Table 137. Tiantan biological Business Overview Table 138. Tiantan biological Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 139. Tiantan biological Human Vaccine Product Portfolio Table 140. Tiantan biological Recent Development Table 141. Changchun Baike Company Information Table 142. Changchun Baike Business Overview Table 143. Changchun Baike Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 144. Changchun Baike Human Vaccine Product Portfolio Table 145. Changchun Baike Recent Development Table 146. Adimmune Company Information Table 147. Adimmune Business Overview Table 148. Adimmune Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 149. Adimmune Human Vaccine Product Portfolio Table 150. Adimmune Recent Development Table 151. Zhongyianke Biotech Company Information Table 152. Zhongyianke Biotech Business Overview Table 153. Zhongyianke Biotech Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 154. Zhongyianke Biotech Human Vaccine Product Portfolio Table 155. Zhongyianke Biotech Recent Development Table 156. Bharat Biotech Company Information Table 157. Bharat Biotech Business Overview Table 158. Bharat Biotech Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 159. Bharat Biotech Human Vaccine Product Portfolio Table 160. Bharat Biotech Recent Development Table 161. Bavarian Nordic Company Information Table 162. Bavarian Nordic Business Overview Table 163. Bavarian Nordic Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 164. Bavarian Nordic Human Vaccine Product Portfolio Table 165. Bavarian Nordic Recent Development Table 166. Sanofi-Pasteur Company Information Table 167. Sanofi-Pasteur Business Overview Table 168. Sanofi-Pasteur Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 169. Sanofi-Pasteur Human Vaccine Product Portfolio Table 170. Sanofi-Pasteur Recent Development Table 171. Indian Immunologicals Company Information Table 172. Indian Immunologicals Business Overview Table 173. Indian Immunologicals Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 174. Indian Immunologicals Human Vaccine Product Portfolio Table 175. Indian Immunologicals Recent Development Table 176. KANGH Company Information Table 177. KANGH Business Overview Table 178. KANGH Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 179. KANGH Human Vaccine Product Portfolio Table 180. KANGH Recent Development Table 181. Henan Grand Biopharma Company Information Table 182. Henan Grand Biopharma Business Overview Table 183. Henan Grand Biopharma Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 184. Henan Grand Biopharma Human Vaccine Product Portfolio Table 185. Henan Grand Biopharma Recent Development Table 186. ZhongKe Biopharm Company Information Table 187. ZhongKe Biopharm Business Overview Table 188. ZhongKe Biopharm Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 189. ZhongKe Biopharm Human Vaccine Product Portfolio Table 190. ZhongKe Biopharm Recent Development Table 191. Zhuoyi Biological Company Information Table 192. Zhuoyi Biological Business Overview Table 193. Zhuoyi Biological Human Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 194. Zhuoyi Biological Human Vaccine Product Portfolio Table 195. Zhuoyi Biological Recent Development Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. Human Vaccine Distributors List Table 199. Human Vaccine Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. Human Vaccine Product Image Figure 2. Global Human Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Human Vaccine Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Human Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Varicella Image Figure 10. Influenza Image Figure 11. Polio Image Figure 12. Hepatitis A Image Figure 13. Rabies Image Figure 14. BCG Image Figure 15. Hepatitis B Image Figure 16. Pertussis, Diphtheria, Tetanus Image Figure 17. Pneumococcal Image Figure 18. Rota vaccine Image Figure 19. Global Human Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Human Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Human Vaccine Sales Volume Share by Type (2021-2032) Figure 22. Global Human Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Human Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Human Vaccine Sales Value Share by Type (2021-2032) Figure 25. Adults Image Figure 26. Children Image Figure 27. Global Human Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 28. Global Human Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Human Vaccine Sales Volume Share by Application (2021-2032) Figure 30. Global Human Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Human Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Human Vaccine Sales Value Share by Application (2021-2032) Figure 33. Global Human Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 34. Global Human Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Human Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Human Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. North America Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 44. South America Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Human Vaccine Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Human Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Human Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Human Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Human Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Human Vaccine Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Human Vaccine Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella
  • Influenza
  • Polio
  • Hepatitis A
  • Rabies
  • BCG
  • Hepatitis B
  • Pertussis, Diphtheria, Tetanus
  • Pneumococcal
  • Rota vaccine
Applications
  • Adults
  • Children
Companies covered
  • CNBG
  • Changsheng Life
  • Zhifei
  • ChengDa Bio
  • Kangtai
  • SINOVAC BIOTECH
  • Hissen
  • Walvax Biotechnology
  • GSK
  • SANOFI
  • Rong An
  • NuoCheng Bio
  • Hualan Bio
  • Tiantan biological
  • Changchun Baike
  • Adimmune
  • Zhongyianke Biotech
  • Bharat Biotech
  • Bavarian Nordic
  • Sanofi-Pasteur
  • Indian Immunologicals
  • KANGH
  • Henan Grand Biopharma
  • ZhongKe Biopharm
  • Zhuoyi Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Human Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Human Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Vaccine Market Dynamics
  1. 2.1 Human Vaccine Industry Trends
  2. 2.2 Human Vaccine Industry Drivers
  3. 2.3 Human Vaccine Industry Opportunities and Challenges
  4. 2.4 Human Vaccine Industry Restraints
3 Human Vaccine Market by Company
  1. 3.1 Global Human Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Human Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Human Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Human Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Human Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Vaccine Company Product Type and Application
  8. 3.8 Global Human Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Vaccine Market by Type
  1. 4.1 Human Vaccine Type Introduction
  2. 4.1.1 Varicella
  3. 4.1.2 Influenza
  4. 4.1.3 Polio
  5. 4.1.4 Hepatitis A
  6. 4.1.5 Rabies
  7. 4.1.6 BCG
  8. 4.1.7 Hepatitis B
  9. 4.1.8 Pertussis, Diphtheria, Tetanus
  10. 4.1.9 Pneumococcal
  11. 4.1.10 Rota vaccine
  12. 4.2 Global Human Vaccine Sales Volume by Type
  13. 4.2.1 Global Human Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Human Vaccine Sales Volume by Type (2021-2032)
  15. 4.2.3 Global Human Vaccine Sales Volume Share by Type (2021-2032)
  16. 4.3 Global Human Vaccine Sales Value by Type
  17. 4.3.1 Global Human Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Human Vaccine Sales Value by Type (2021-2032)
  19. 4.3.3 Global Human Vaccine Sales Value Share by Type (2021-2032)
5 Human Vaccine Market by Application
  1. 5.1 Human Vaccine Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Human Vaccine Sales Volume by Application
  5. 5.2.1 Global Human Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Human Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Human Vaccine Sales Value by Application
  9. 5.3.1 Global Human Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Human Vaccine Sales Value Share by Application (2021-2032)
6 Human Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Human Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Human Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Human Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Human Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Human Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Human Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Human Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Human Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Vaccine Sales Value Share by Country, 2025 VS 2032
7 Human Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Human Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Human Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Human Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Human Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CNBG
  2. 8.1.1 CNBG Company Information
  3. 8.1.2 CNBG Business Overview
  4. 8.1.3 CNBG Human Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CNBG Human Vaccine Product Portfolio
  6. 8.1.5 CNBG Recent Developments
  7. 8.2 Changsheng Life
  8. 8.2.1 Changsheng Life Company Information
  9. 8.2.2 Changsheng Life Business Overview
  10. 8.2.3 Changsheng Life Human Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Changsheng Life Human Vaccine Product Portfolio
  12. 8.2.5 Changsheng Life Recent Developments
  13. 8.3 Zhifei
  14. 8.3.1 Zhifei Company Information
  15. 8.3.2 Zhifei Business Overview
  16. 8.3.3 Zhifei Human Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zhifei Human Vaccine Product Portfolio
  18. 8.3.5 Zhifei Recent Developments
  19. 8.4 ChengDa Bio
  20. 8.4.1 ChengDa Bio Company Information
  21. 8.4.2 ChengDa Bio Business Overview
  22. 8.4.3 ChengDa Bio Human Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ChengDa Bio Human Vaccine Product Portfolio
  24. 8.4.5 ChengDa Bio Recent Developments
  25. 8.5 Kangtai
  26. 8.5.1 Kangtai Company Information
  27. 8.5.2 Kangtai Business Overview
  28. 8.5.3 Kangtai Human Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kangtai Human Vaccine Product Portfolio
  30. 8.5.5 Kangtai Recent Developments
  31. 8.6 SINOVAC BIOTECH
  32. 8.6.1 SINOVAC BIOTECH Company Information
  33. 8.6.2 SINOVAC BIOTECH Business Overview
  34. 8.6.3 SINOVAC BIOTECH Human Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SINOVAC BIOTECH Human Vaccine Product Portfolio
  36. 8.6.5 SINOVAC BIOTECH Recent Developments
  37. 8.7 Hissen
  38. 8.7.1 Hissen Company Information
  39. 8.7.2 Hissen Business Overview
  40. 8.7.3 Hissen Human Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hissen Human Vaccine Product Portfolio
  42. 8.7.5 Hissen Recent Developments
  43. 8.8 Walvax Biotechnology
  44. 8.8.1 Walvax Biotechnology Company Information
  45. 8.8.2 Walvax Biotechnology Business Overview
  46. 8.8.3 Walvax Biotechnology Human Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Walvax Biotechnology Human Vaccine Product Portfolio
  48. 8.8.5 Walvax Biotechnology Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK Human Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GSK Human Vaccine Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 SANOFI
  56. 8.10.1 SANOFI Company Information
  57. 8.10.2 SANOFI Business Overview
  58. 8.10.3 SANOFI Human Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 SANOFI Human Vaccine Product Portfolio
  60. 8.10.5 SANOFI Recent Developments
  61. 8.11 Rong An
  62. 8.11.1 Rong An Company Information
  63. 8.11.2 Rong An Business Overview
  64. 8.11.3 Rong An Human Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Rong An Human Vaccine Product Portfolio
  66. 8.11.5 Rong An Recent Developments
  67. 8.12 NuoCheng Bio
  68. 8.12.1 NuoCheng Bio Company Information
  69. 8.12.2 NuoCheng Bio Business Overview
  70. 8.12.3 NuoCheng Bio Human Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 NuoCheng Bio Human Vaccine Product Portfolio
  72. 8.12.5 NuoCheng Bio Recent Developments
  73. 8.13 Hualan Bio
  74. 8.13.1 Hualan Bio Company Information
  75. 8.13.2 Hualan Bio Business Overview
  76. 8.13.3 Hualan Bio Human Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hualan Bio Human Vaccine Product Portfolio
  78. 8.13.5 Hualan Bio Recent Developments
  79. 8.14 Tiantan biological
  80. 8.14.1 Tiantan biological Company Information
  81. 8.14.2 Tiantan biological Business Overview
  82. 8.14.3 Tiantan biological Human Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Tiantan biological Human Vaccine Product Portfolio
  84. 8.14.5 Tiantan biological Recent Developments
  85. 8.15 Changchun Baike
  86. 8.15.1 Changchun Baike Company Information
  87. 8.15.2 Changchun Baike Business Overview
  88. 8.15.3 Changchun Baike Human Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Changchun Baike Human Vaccine Product Portfolio
  90. 8.15.5 Changchun Baike Recent Developments
  91. 8.16 Adimmune
  92. 8.16.1 Adimmune Company Information
  93. 8.16.2 Adimmune Business Overview
  94. 8.16.3 Adimmune Human Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Adimmune Human Vaccine Product Portfolio
  96. 8.16.5 Adimmune Recent Developments
  97. 8.17 Zhongyianke Biotech
  98. 8.17.1 Zhongyianke Biotech Company Information
  99. 8.17.2 Zhongyianke Biotech Business Overview
  100. 8.17.3 Zhongyianke Biotech Human Vaccine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Zhongyianke Biotech Human Vaccine Product Portfolio
  102. 8.17.5 Zhongyianke Biotech Recent Developments
  103. 8.18 Bharat Biotech
  104. 8.18.1 Bharat Biotech Company Information
  105. 8.18.2 Bharat Biotech Business Overview
  106. 8.18.3 Bharat Biotech Human Vaccine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Bharat Biotech Human Vaccine Product Portfolio
  108. 8.18.5 Bharat Biotech Recent Developments
  109. 8.19 Bavarian Nordic
  110. 8.19.1 Bavarian Nordic Company Information
  111. 8.19.2 Bavarian Nordic Business Overview
  112. 8.19.3 Bavarian Nordic Human Vaccine Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bavarian Nordic Human Vaccine Product Portfolio
  114. 8.19.5 Bavarian Nordic Recent Developments
  115. 8.20 Sanofi-Pasteur
  116. 8.20.1 Sanofi-Pasteur Company Information
  117. 8.20.2 Sanofi-Pasteur Business Overview
  118. 8.20.3 Sanofi-Pasteur Human Vaccine Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Sanofi-Pasteur Human Vaccine Product Portfolio
  120. 8.20.5 Sanofi-Pasteur Recent Developments
  121. 8.21 Indian Immunologicals
  122. 8.21.1 Indian Immunologicals Company Information
  123. 8.21.2 Indian Immunologicals Business Overview
  124. 8.21.3 Indian Immunologicals Human Vaccine Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Indian Immunologicals Human Vaccine Product Portfolio
  126. 8.21.5 Indian Immunologicals Recent Developments
  127. 8.22 KANGH
  128. 8.22.1 KANGH Company Information
  129. 8.22.2 KANGH Business Overview
  130. 8.22.3 KANGH Human Vaccine Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 KANGH Human Vaccine Product Portfolio
  132. 8.22.5 KANGH Recent Developments
  133. 8.23 Henan Grand Biopharma
  134. 8.23.1 Henan Grand Biopharma Company Information
  135. 8.23.2 Henan Grand Biopharma Business Overview
  136. 8.23.3 Henan Grand Biopharma Human Vaccine Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Henan Grand Biopharma Human Vaccine Product Portfolio
  138. 8.23.5 Henan Grand Biopharma Recent Developments
  139. 8.24 ZhongKe Biopharm
  140. 8.24.1 ZhongKe Biopharm Company Information
  141. 8.24.2 ZhongKe Biopharm Business Overview
  142. 8.24.3 ZhongKe Biopharm Human Vaccine Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 ZhongKe Biopharm Human Vaccine Product Portfolio
  144. 8.24.5 ZhongKe Biopharm Recent Developments
  145. 8.25 Zhuoyi Biological
  146. 8.25.1 Zhuoyi Biological Company Information
  147. 8.25.2 Zhuoyi Biological Business Overview
  148. 8.25.3 Zhuoyi Biological Human Vaccine Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Zhuoyi Biological Human Vaccine Product Portfolio
  150. 8.25.5 Zhuoyi Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Vaccine Value Chain Analysis
  2. 9.1.1 Human Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Vaccine Sales Mode & Process
  6. 9.2 Human Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Vaccine Distributors
  9. 9.2.3 Human Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst